| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,122.7 | 794.9 |
| Profit before tax | 283.7 | 291.8 |
| Net income | 206.5 | 209.5 |
| EPS (diluted, $ a share) | $1.96 | $2.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -1.4% |
|---|---|
| Revenue, year on year | +41.2% |
| Operating margin | 29.5% |
10-Q filed with the SEC, NASDAQ: NBIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Neurocrine Biosciences Inc: key numbers
- Share price
- $165.92Close, Nov 17
- Market cap
- $16.8B
- Shares outstanding
- 101.22MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Neurocrine Biosciences Inc
All →Neurocrine Biosciences Insider George J. Morrow Sells $2.34M of Stock
George J. Morrow sold 15,000 shares of Neurocrine Biosciences Inc at $144.98 to $168.53 a share (average $155.73) in 12 transactions, worth $2.34M in total between Oct 30, 2026 and Nov 3, 2026. Shares held after the trade: 10,386 (-11.1%).
- Value
- $2.34M
- Shares
- 15,000
- Average price
- $155.73
- Holding change
- -11.1%
- Trade date
- Oct 30, 2026 to Nov 3, 2026
Neurocrine Biosciences Financial Results
Neurocrine Biosciences reported third-quarter 2026 total revenue of $1.1 billion, a 41% increase year-over-year, driven by strong sales of INGREZZA and CRENESSITY. The company raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion.
- Term
- Q3 2026
“Our third quarter performance marks another important milestone in Neurocrine’s evolution, with net product sales exceeding $1 billion for the first time, driven by strong underlying demand across our diversified portfolio of first-in-class medicines. This continued growth reinforces the strength of our strategy and expands our capacity to invest in innovation, advance our pipeline and build an enduring biopharmaceutical company.”
Kyle W. Gano, Ph.D., Chief Executive Officer of Neurocrine Biosciences
Neurocrine Biosciences Leadership Change
Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer, succeeding Sanjay Keswani, M.D., effective September 28, 2026. Dr. Roberts will receive an annual base salary of $825,000, a 60% target bonus, and equity grants totaling approximately $1.25 million in target value. Dr. Keswani's departure was described as a mutual agreement, and he will receive severance benefits under the company's existing executive plan.
- Counterparty
- Eiry W. Roberts, M.D.